TSE:TRLTrilogy International Partners Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trilogy International Partners Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$1.30 +0.10 (+8.33 %) (As of 05/28/2020 10:19 AM ET) Add Compare Share Today's RangeC$1.20Now: C$1.30▼C$1.3450-Day RangeC$1.00MA: C$1.23▼C$1.4052-Week RangeC$0.83Now: C$1.30▼C$3.45Volume429,100 shsAverage Volume30,531 shsMarket CapitalizationC$75.43 millionP/E Ratio26.00Dividend Yield1.43%BetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsInsider TradesHeadlinesSocial Media Trilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communication services in Bolivia and New Zealand. The company's communications services include local, international long distance, and roaming services for customers and international visitors roaming on their networks. It also provides fixed broadband communications services to business and residential customers. The company serves 15.9 million customers. Trilogy International Partners Inc. is headquartered in Bellevue, Washington.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTrilogy International Partners has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$2.50, Trilogy International Partners has a potential upside of 92.3% from its current price of C$1.30.Amount of Analyst CoverageTrilogy International Partners has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesTrilogy International Partners has received 209 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTrilogy International Partners has received 144 “underperform” votes. (Add your “underperform” vote.)Community SentimentTrilogy International Partners has received 59.21% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote “Outperform” if you believe TRL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 2.5 Dividend Strength Dividend LeadershipTrilogy International Partners is a leading dividend payer. It pays a dividend yield of 1.43%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthTrilogy International Partners does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Trilogy International Partners is 29.73 %. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trilogy International Partners insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$540,000.00 in company stock and sold C$0.00 in company stock. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Trilogy International Partners are expected to grow in the coming year, from C($0.40) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trilogy International Partners is 26.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Trilogy International Partners is 26.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.13.Price to Earnings Growth RatioTrilogy International Partners has a PEG Ratio of 21.78. PEG Ratios above 1 indicate that a company could be overvalued. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 2.5Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.65 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolTSE:TRL Previous SymbolTSE:AQX.A CUSIPN/A CIKN/A Webwww.trilogy-international.co... Phone+1-425-4585900Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.73Price-To-Earnings Trailing P/E Ratio26.00 Forward P/E RatioN/A P/E Growth21.78 Sales & Book Value Annual SalesC$693.93 million Price / Sales0.11 Cash FlowC$1.58 per share Price / Cash Flow0.82 Book ValueC($1.12) per share Price / Book-1.17Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees1,821 Outstanding Shares58,024,000Market CapC$75.43 million Next Earnings Date6/3/2020 (Estimated) OptionableNot Optionable TSX:TRL Rates by TradingView Receive TRL News and Ratings via Email Sign-up to receive the latest news and ratings for TRL and its competitors with MarketBeat's FREE daily newsletter. Trilogy International Partners (TSE:TRL) Frequently Asked Questions How has Trilogy International Partners' stock been impacted by COVID-19 (Coronavirus)? Trilogy International Partners' stock was trading at C$1.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TRL stock has decreased by 31.6% and is now trading at C$1.30. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Trilogy International Partners? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trilogy International Partners. When is Trilogy International Partners' next earnings date? Trilogy International Partners is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for Trilogy International Partners. How were Trilogy International Partners' earnings last quarter? Trilogy International Partners Inc (TSE:TRL) announced its quarterly earnings results on Tuesday, March, 24th. The specialty pharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.44. The specialty pharmaceutical company earned $219.23 million during the quarter. View Trilogy International Partners' earnings history. What price target have analysts set for TRL? 2 brokers have issued 1-year price targets for Trilogy International Partners' shares. Their forecasts range from C$1.70 to C$3.30. On average, they expect Trilogy International Partners' stock price to reach C$2.50 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price. View analysts' price targets for Trilogy International Partners. Has Trilogy International Partners been receiving favorable news coverage? News headlines about TRL stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trilogy International Partners earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutTrilogy International Partners. Who are some of Trilogy International Partners' key competitors? Some companies that are related to Trilogy International Partners include BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Recce Pharmaceuticals (RCE), Futura Medical (FUM), NanoViricides (NNVC), Vita Life Sciences (VLS), Pharmaxis (PXS), Sareum (SAR), Avivagen (VIV), Antisense Therapeutics (ANP), China Pharma (CPHI), Patrys (PAB), Cathay International (CTI) and N4 Pharma (N4P). View all competitors. What other stocks do shareholders of Trilogy International Partners own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trilogy International Partners investors own include Acerus Pharmaceuticals (ASP), Emera (EMA), Millicom International Cellular (MIICF), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONCYF), CSX (CSX), Check Cap (CHEK), Citizens Financial Group (CFG), Cboe Global Markets (CBOE) and CAE (CAE). Who are Trilogy International Partners' key executives? Trilogy International Partners' management team includes the following people: Mr. John William Stanton, Chairman (Age 64)Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 63)Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 66)Mr. Erik Mickels, Sr. VP & CFOMr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec. What is Trilogy International Partners' stock symbol? Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL." How do I buy shares of Trilogy International Partners? Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Trilogy International Partners' stock price today? One share of TRL stock can currently be purchased for approximately C$1.30. How big of a company is Trilogy International Partners? Trilogy International Partners has a market capitalization of C$75.43 million and generates C$693.93 million in revenue each year. Trilogy International Partners employs 1,821 workers across the globe. What is Trilogy International Partners' official website? The official website for Trilogy International Partners is www.trilogy-international.co.... How can I contact Trilogy International Partners? Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900. This page was last updated on 5/28/2020 by MarketBeat.com Staff
